Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines.
Chem Commun (Camb)
; 54(69): 9655-9658, 2018 Aug 23.
Article
en En
| MEDLINE
| ID: mdl-30101273
ABSTRACT
Cyclic di-GMP (CDG) was applied to MUC1 glycopeptide-based cancer vaccines with physical mixing and built-in (at 2'-OH of CDG) strategies for activating the STING pathway. CDG in both strategies behaved as a potent immunostimulant and contributed to high titers of IgG antibodies and the expression of multiple cytokines.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Glicopéptidos
/
GMP Cíclico
/
Vacunas contra el Cáncer
/
Proteínas de la Membrana
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Chem Commun (Camb)
Asunto de la revista:
QUIMICA
Año:
2018
Tipo del documento:
Article